Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236674 | 0.91 | PTPN1 (0.39) | PTPN1PTPRA | |
| SCHEMBL10236444 | 0.89 | — | — | |
| SCHEMBL10236453 | 0.87 | MEN1 (0.39) | — | |
| SCHEMBL10236672 | 0.85 | PTPN1 (0.38) | PTPN1PTPRA | |
| SCHEMBL10236837 | 0.84 | — | — | |
| SCHEMBL13189786 | 0.84 | — | — | |
| SCHEMBL10236675 | 0.83 | PTPN1 (0.42) | PTPN1PTPRAACLY | |
| SCHEMBL10236569 | 0.83 | — | — | |
| SCHEMBL10236841 | 0.82 | — | — | |
| SCHEMBL10237073 | 0.81 | KMT2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403860-B1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010101967-A2 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | PTPN1 1081/4885PTPRA 828/4885ACLY 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.